Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.60
HZNP's Cash to Debt is ranked lower than
64% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. HZNP: 0.60 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 1.02 Max: N/A
Current: 0.6
Equity to Asset 0.42
HZNP's Equity to Asset is ranked lower than
78% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HZNP: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.47 Max: 0.7
Current: 0.42
-0.77
0.7
F-Score: 5
Z-Score: 0.92
M-Score: -0.75
WACC vs ROIC
13.86%
2.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.27
HZNP's Operating margin (%) is ranked lower than
61% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. HZNP: 4.27 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s Operating margin (%) Range Over the Past 10 Years
Min: -1841.5  Med: -418.56 Max: -2.86
Current: 4.27
-1841.5
-2.86
Net-margin (%) -2.61
HZNP's Net-margin (%) is ranked lower than
77% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. HZNP: -2.61 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s Net-margin (%) Range Over the Past 10 Years
Min: -1635.12  Med: -465.90 Max: -88.77
Current: -2.61
-1635.12
-88.77
ROE (%) -1.91
HZNP's ROE (%) is ranked lower than
73% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. HZNP: -1.91 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s ROE (%) Range Over the Past 10 Years
Min: -523.78  Med: -115.60 Max: -57.66
Current: -1.91
-523.78
-57.66
ROA (%) -0.83
HZNP's ROA (%) is ranked lower than
70% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. HZNP: -0.83 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s ROA (%) Range Over the Past 10 Years
Min: -176.97  Med: -63.12 Max: -31.86
Current: -0.83
-176.97
-31.86
ROC (Joel Greenblatt) (%) 222.48
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. HZNP: 222.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4895.85  Med: -2664.68 Max: -154.09
Current: 222.48
-4895.85
-154.09
Revenue Growth (3Y)(%) 66.40
HZNP's Revenue Growth (3Y)(%) is ranked higher than
96% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HZNP: 66.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -7.30 Max: 66.4
Current: 66.4
0
66.4
EPS Growth (3Y)(%) -37.00
HZNP's EPS Growth (3Y)(%) is ranked lower than
89% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. HZNP: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HZNP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.00 Max: -37
Current: -37
» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

HZNP Guru Trades in Q1 2015

Jim Simons 359,430 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones 45,508 sh (-83.43%)
Steven Cohen 233,900 sh (-91.05%)
» More
Q2 2015

HZNP Guru Trades in Q2 2015

RS Investment Management 964,160 sh (New)
Steve Mandel 3,204,972 sh (New)
Jim Simons 1,216,800 sh (+238.54%)
Paul Tudor Jones 137,400 sh (+201.92%)
Steven Cohen 325,000 sh (+38.95%)
» More
Q3 2015

HZNP Guru Trades in Q3 2015

Ron Baron 31,999 sh (New)
Steve Mandel 15,600,988 sh (+386.77%)
RS Investment Management 1,383,550 sh (+43.50%)
Jim Simons 465,912 sh (-61.71%)
Paul Tudor Jones 12,038 sh (-91.24%)
Steven Cohen 900 sh (-99.72%)
» More
Q4 2015

HZNP Guru Trades in Q4 2015

Ken Heebner 205,000 sh (New)
RS Investment Management 2,210,448 sh (+59.77%)
Jim Simons 302,400 sh (-35.10%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Horizon Pharma PLC

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
Forward P/E 3.00
HZNP's Forward P/E is ranked higher than
98% of the 412 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.50 vs. HZNP: 3.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.17
HZNP's P/B is ranked higher than
57% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 2.17 )
Ranked among companies with meaningful P/B only.
HZNP' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 2.42 Max: 14.89
Current: 2.17
0.8
14.89
P/S 4.01
HZNP's P/S is ranked lower than
70% of the 935 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. HZNP: 4.01 )
Ranked among companies with meaningful P/S only.
HZNP' s P/S Range Over the Past 10 Years
Min: 1.47  Med: 4.72 Max: 19.46
Current: 4.01
1.47
19.46
PFCF 63.05
HZNP's PFCF is ranked lower than
80% of the 464 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.12 vs. HZNP: 63.05 )
Ranked among companies with meaningful PFCF only.
HZNP' s PFCF Range Over the Past 10 Years
Min: 45.11  Med: 74.19 Max: 433
Current: 63.05
45.11
433
POCF 53.21
HZNP's POCF is ranked lower than
77% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. HZNP: 53.21 )
Ranked among companies with meaningful POCF only.
HZNP' s POCF Range Over the Past 10 Years
Min: 38.27  Med: 62.59 Max: 185.57
Current: 53.21
38.27
185.57
EV-to-EBIT 120.29
HZNP's EV-to-EBIT is ranked lower than
96% of the 804 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.88 vs. HZNP: 120.29 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.90 Max: 219.8
Current: 120.29
-775.4
219.8
EV-to-EBITDA 23.16
HZNP's EV-to-EBITDA is ranked lower than
69% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.62 vs. HZNP: 23.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.90 Max: 518
Current: 23.16
-608
518
Current Ratio 2.97
HZNP's Current Ratio is ranked higher than
62% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. HZNP: 2.97 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.94 Max: 4.39
Current: 2.97
0.16
4.39
Quick Ratio 2.90
HZNP's Quick Ratio is ranked higher than
70% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. HZNP: 2.90 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.80 Max: 4.27
Current: 2.9
0.16
4.27
Days Inventory 37.99
HZNP's Days Inventory is ranked higher than
89% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. HZNP: 37.99 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 59.25 Max: 184.95
Current: 37.99
13.1
184.95
Days Sales Outstanding 130.93
HZNP's Days Sales Outstanding is ranked lower than
80% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. HZNP: 130.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 88.33 Max: 124.99
Current: 130.93
67.08
124.99
Days Payable 122.75
HZNP's Days Payable is ranked higher than
74% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. HZNP: 122.75 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 97.38  Med: 215.25 Max: 410.36
Current: 122.75
97.38
410.36

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.63
HZNP's Price/Projected FCF is ranked lower than
67% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. HZNP: 3.63 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.23  Med: 14.99 Max: 409.33
Current: 3.63
4.23
409.33
Price/Median PS Value 0.85
HZNP's Price/Median PS Value is ranked higher than
76% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. HZNP: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 1.01 Max: 3.68
Current: 0.85
0.37
3.68
Price/Graham Number 3.67
HZNP's Price/Graham Number is ranked lower than
73% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. HZNP: 3.67 )
Ranked among companies with meaningful Price/Graham Number only.
HZNP' s Price/Graham Number Range Over the Past 10 Years
Min: 0.17  Med: 1.03 Max: 8.8
Current: 3.67
0.17
8.8
Earnings Yield (Greenblatt) (%) 0.79
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HZNP: 0.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.70 Max: 0.9
Current: 0.79
0.5
0.9

More Statistics

Revenue(Mil) $616
EPS $ -0.21
Beta1.75
Short Percentage of Float12.86%
52-Week Range $12.86 - 39.49
Shares Outstanding(Mil)159.29

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 756 1,038 1,164
EPS($) 1.88 3.55 5.37
EPS without NRI($) 1.88 3.55 5.37

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving... Feb 10 2016
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement Feb 08 2016
Stock Watchout on Drugs - Generic -- Mylan, Neurocrine Biosciences, Horizon Pharma, and Zoetis Feb 02 2016
Horizon Pharma plc to Host Fourth Quarter 2015 Conference Call and Webcast on February 29, 2016 Jan 29 2016
Horizon Pharma plc to Host Fourth Quarter 2015 Conference Call and Webcast on February 29, 2016 Jan 29 2016
Horizon Pharma plc to Participate in Three Investor Conferences in February Jan 28 2016
Horizon Pharma plc to Participate in Three Investor Conferences in February Jan 28 2016
The Zacks Analyst Blog Highlights: Horizon Pharma, Axiall, Trina Solar, Deep Value ETF and... Jan 25 2016
HORIZON PHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers Jan 14 2016
Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC Jan 14 2016
Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC Jan 14 2016
Biotech Stock Roundup: Baxalta - Shire to Combine, JPM Healthcare Conference in Focus Jan 13 2016
Horizon (HZNP) Ups View on Crealta Holdings Deal, Shares Up Jan 13 2016
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy... Jan 13 2016
Top stock picks for 2016: Pro Jan 13 2016
Drug Stocks Mixed On Guidance Updates Jan 12 2016
5 Smart PIIGS Stocks to Buy Now Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK